OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, May 05, 2012

paywalled: Psychological Distress of the Bereaved Seeking Medical Counseling at a Cancer Center



 Blogger's Note/Opinion: the abstract is one of a few which is written in plain english and with an empathetic 'tone' both of which set it apart from many psycho-oncology papers

Psychological Distress of the Bereaved Seeking Medical Counseling at a Cancer Center

Abstract

Objective The death of a loved one is one of the most stressful events in life and is related to the physical and psychological wellbeing of the bereaved. Some bereaved individuals seek medical counseling to alleviate their distress. However, no studies have focused on the bereaved who have lost a loved one to cancer and have asked for medical help at a cancer center as a result. The aim of this study was to investigate the distress of the bereaved who sought consultation, as basic information for considering support.
Methods We conducted a survey of people consulting outpatient services for bereaved families between April 2007 and September 2009. Data were obtained from medical records at initial consultation and qualitatively analyzed by content analysis using all statements related to their distress.
Results Their statements were classified into 11 categories, which were further classified into six themes. The main categories of bereavement-related distress were as follows: (i) regret; (ii) anger; (iii) memories; (iv) loneliness; (v) anxiety; and (vi) hopelessness. ‘Regret’ was frequently recognized in their distress and it includes some points related to the cancer trajectory. 
Conclusions Psychological distresses of the bereaved who have lost a loved one and have asked for medical counseling are revealed. Their distresses are strongly related to the cancer trajectory of a family member. Some of these distresses are related to medical misunderstanding about the course of cancer. These findings might provide basic information for considering their appropriate treatment.

video: doctor who restricted his wife's appointment to one problem only - video



Blogger's Note/Opinion: while this media report is from Canada (Manitoba) this is not a country-specific issue, it is, however, not patient-centered nor patient-friendly care, watch media for upcoming 'apologies'

Canada News Videos

 'Assembly line medicine' (video)

paywalled: US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology (breast/ovarian mutation)



US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology

US firm corners exclusive license for RAD51C cancer gene

 
"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.
“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University"

Editorial: Serrated Polyposis: The Last (or Only the Latest - Frontier of Familial Polyposis (Lynch Syndrome/familial/pre-malignant adenomas)



 Wiki:  Sessile serrated adenoma

 In gastroenterology, a sessile serrated adenoma (abbreviated SSA), also known as sessile serrated polyp (abbreviated SSP), is a premalignant flat (or sessile) lesions of the colon, predominantly seen in the cecum and ascending colon.



Editorial: Serrated Polyposis: The Last (or Only the Latest|[quest]|) Frontier of Familial Polyposis|[quest]| : The American Journal of Gastroenterology

The American Journal of Gastroenterology 107, 779-781 (May 2012) | doi:10.1038/ajg.2012.62

Editorial: Serrated Polyposis: The Last (or Only the Latest?) Frontier of Familial Polyposis?

Stephen J Lanspa, Dennis J Ahnen and Henry T Lynch
Serrated polyps are thought to be precursors of ~15% of colorectal cancers and clinical criteria for a serrated polyposis (SP) syndrome have been proposed. In this issue of American Journal of Gastroenterology, Win et al. report that family members of individuals who meet the clinical criteria for SP are at increased risk for colorectal and possibly pancreatic cancer. The important data presented by Win et al. strongly support the concept that familial SP exists and help define the patterns of risk in this syndrome. The paper also illustrates the difficulties of trying to define a genetic syndrome on the basis of largely retrospective clinical data and highlights the importance of efforts to define the genetic basis of familial SP and to study these families in a systematic, prospective manner.

paywalled: Dosage Effect of BRCA1 and BRCA 2 Mutated Allelic Transcript (French Canadian)



Dosage Effect of BRCA1/2-Mutated Allelic Transcript:

We hypothesized that the transcriptome of primary cultures of morphologically normal ovarian surface epithelial cells could be altered by the presence of a heterozygous BRCA1 or BRCA2 mutation.

We aimed to discover early events associated with ovarian carcinogenesis, which could represent putative targets for preventive strategies of this silent killer tumor. We identified the first molecular signature associated with French Canadian BRCA1 or BRCA2 founder mutations in morphologically normal ovarian epithelial cells. We discovered that wild-type and mutated BRCA2 allelic transcripts were expressed not only in morphologically normal but also in tumor cells from BRCA2-8765delAG carriers. Further analysis of morphologically normal ovarian and tumor cells from BRCA1-4446C>T carriers lead to the same observation.

Our data support the idea that one single hit in BRCA1 or BRCA2 is sufficient to alter the transcriptome of phenotypically normal ovarian epithelial cells. The highest level of BRCA2-mutated allele transcript expression was measured in cells originating from the most aggressive ovarian tumor. The penetrance of the mutation and the aggressiveness of the related tumor could depend on a dosage effect of the mutated allele transcript.

paywalled: Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling



Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling: Publication year: 2012


Source: Gynecologic Oncology

Objective We sought to determine whether prophylactic oophorectomy rates changed after the introduction of a 2007 health plan clinical guideline recommending systematic referral to a genetic counselor for women with a personal or family history suggestive of an inherited susceptibility to breast/ovarian cancer.

Methods We conducted a retrospective cohort study of female members of Group Health, an integrated delivery system in Washington State. Subjects were women aged ≥35years during 2004–2009 who reported a personal or family history consistent with an inherited susceptibility to breast/ovarian cancer. Personal and family history information was collected on a questionnaire completed when the women had a mammogram. We ascertained oophorectomies from automated claims data and determined whether surgeries were prophylactic by medical chart review.....

Results Prophylactic oophorectomy rates were relatively unchanged after compared to before the guideline change, 1.0 versus 0.8/1,000 person-years, (IRR=1.2; 95% CI: 0.7-2.0), whereas bilateral oophorectomy rates for other indications decreased. Genetic counseling receipt rates doubled after the guideline change (95% CI: 1.7-2.4) from 5.1 to 10.2/1,000 person-years. During the study, bilateral oophorectomy rates were appreciably greater in women who saw a genetic counselor compared to those who did not regardless of whether they received genetic testing as part of their counseling.

Conclusion A doubling in genetic counseling receipt rates lends support to the idea that the guideline issuance contributed to sustained rates of prophylactic oophorectomies in more recent years.

Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV



Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV: Publication year: 2012

Source: Gynecologic Oncology


Objectives This study evaluates whether a molecular targeted therapy with the farnesyl transferase inhibitor lonafarnib added to standard chemotherapy in first-line treatment of advanced ovarian cancer (OC) could improve progression-free (PFS) and overall survival (OS).

Patients and Methods We performed a prospective randomized phase II study to compare standard therapy carboplatin (C; AUC 5) and paclitaxel (T; 175mg/m2) in primary advanced OC with or without lonafarnib (L). Lonafarnib was given in a dose of 100mg orally twice a day during chemotherapy and was increased afterwards to 200mg up to six months as a maintenance therapy.

Results 105 patients were recruited( 53 patients were randomised to receive LTC, 52 to TC). Hematologic toxicity was similar in both arms. Grade 3 and 4 non-hematological toxicity, occurred significantly more often with LTC (23% versus 4%, p=0.005) and was associated with a higher dropout rate. PFS and OS were not significantly different among both arms. The LTC arm showed inferiority in the stratum with residual tumor of more than 1cm:.....

Conclusion The addition of lonafarnib did not improve PFS or OS. Patients with a residual tumor of more than 1cm had significantly shorter PFS and OS. Incorporation of lonafarnib into future studies for primary therapy of OC is not recommended.

paywalled: Gynecologic Oncology - Green Tea for Ovarian Cancer Prevention and Treatment: A Systematic Review of the in Vitro, in Vivo and Epidemiological Studies



ScienceDirect.com - Gynecologic Oncology - Green Tea for Ovarian Cancer Prevention and Treatment: A Systematic Review of the in Vitro, in Vivo and Epidemiological Studies

Abstract

Objective

This systematic review was conducted to examine the effects of green tea or green tea components on the prevention and progression of epithelial ovarian cancer.

Methods

Using Medline, EMBASE and SciVerse (last researched: July 2011), we retrieved 22 articles including 5 epidemiological studies.

Results

In epithelial ovarian cancer cell lines, green tea and green tea components have been shown to down regulate the expression of proteins involved in inflammation, cell signalization, cell motility and angiogenesis. Green tea and green tea components would induce apoptosis and could potentiate the effects of cisplatin, a chemotherapeutic agent. In human observational studies, significant associations between green tea intake and both decreased ovarian cancer occurrence and better prognosis were reported.

Conclusions

Available literature suggests potential molecular targets for green tea in ovarian cancer treatment and also provides data supporting the clinical evaluation of the role of green tea or green tea components in ovarian cancer prevention and treatment.

Highlights

► Green tea decreases ovarian cancer-associated protein expression in cell lines.
► Green tea-fed mice develop smaller, less vascularized ovarian cancer xenografts.
► Green tea intake could decrease ovarian cancer occurrence and recurrence in women.

EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov Phase 1 solid tumors



EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov

Official Title: EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial
This study is not yet open for participant recruitment.
Verified May 2012 by M.D. Anderson Cancer Center

First Received on May 2, 2012.   No Changes Posted
Sponsor: M.D. Anderson Cancer Center
Collaborator: Ovarian Cancer Research Fund
Information provided by (Responsible Party): M.D. Anderson Cancer Center ( M.D. Anderson Cancer Center )
ClinicalTrials.gov Identifier: NCT01591356


  Purpose
The goal of this clinical research study is to learn about the safety of siRNA-EphA2-DOPC when given to patients with advanced, recurrent cancer. Researchers also want to learn the highest tolerable dose of this drug that can be given.
siRNA-EphA2-DOPC is designed to shut down the activity of a gene that causes tumor growth.

Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer - Full Text View - ClinicalTrials.gov (clinical trials)



Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer - Full Text View - ClinicalTrials.gov

This study is currently recruiting participants.
Verified May 2012 by Memorial Sloan-Kettering Cancer Center

First Received on April 30, 2012.   Last Updated on May 2, 2012   History of Changes
Sponsor: Memorial Sloan-Kettering Cancer Center
Collaborator: Weill Medical College of Cornell University
Information provided by (Responsible Party): Memorial Sloan-Kettering Cancer Center ( Memorial Sloan-Kettering Cancer Center )
ClinicalTrials.gov Identifier: NCT01591772
  Purpose
The purpose of this study is to learn about possible changes in brain anatomy and function, and in thinking abilities, such as memory skills, in patients with ovarian cancer who receive treatment with chemotherapy. Cancer patients treated with chemotherapy may experience changes in thinking abilities, and these may interfere with quality of life. Most of the research to date has involved patients with breast cancer, and there are no studies in women with ovarian cancer looking at at treatment-related changes in brain anatomy and function.

Friday, May 04, 2012

In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.



In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.


Abstract
INTRODUCTION: Ovarian adenocarcinoma is frequently detected at the late stage, when therapy efficacy is limited and death occurs in up to 50% of the cases. A potential novel treatment for this disease is a monoclonal antibody that recognizes phosphate transporter sodium-dependent phosphate transporter protein 2b (NaPi2b).

MATERIALS AND METHODS: To better understand the expression of this protein in different histologic types of ovarian carcinomas, we immunostained 50 tumor samples with anti-NaPi2b monoclonal antibody MX35 and, in parallel, we assessed the expression of the gene encoding NaPi2b (SCL34A2) by in silico analysis of microarray data.

RESULTS: Both approaches detected higher expression of NaPi2b (SCL34A2) in ovarian carcinoma than in normal tissue. Moreover, a comprehensive analysis indicates that SCL34A2 is the only gene of the several phosphate transporters genes whose expression differentiates normal from carcinoma samples, suggesting it might exert a major role in ovarian carcinomas. Immunohistochemical and mRNA expression data have also shown that 2 histologic subtypes of ovarian carcinoma express particularly high levels of NaPi2b: serous and clear cell adenocarcinomas. Serous adenocarcinomas are the most frequent, contrasting with clear cell carcinomas, rare, and with worse prognosis.

CONCLUSION: This identification of subgroups of patients expressing NaPi2b may be important in selecting cohorts who most likely should be included in future clinical trials, as a recently generated humanized version of MX35 has been developed.


Thursday, May 03, 2012

England: The Cancer Drugs Fund: Guidance to support operation of the Cancer Drugs Fund in 2012-13 : Department of Health - Publications



 Blogger's Note: this is primarily an administrative document, patient/consumer searches for specific drugs are not part of this guidance report

The Cancer Drugs Fund: Guidance to support operation of the Cancer Drugs Fund in 2012-13 : Department of Health - Publications

  • Document type:
    Guidance
  • Author:
    Department of Health
  • Published date:
    23 April 2012
  • Primary audience:
    Health and social care professionals
  • Publication format:
    A4: electronic format only
  • Gateway reference:
    17340
  • Pages:
    14
  • Supersedes/replaces:
  • Copyright holder:
    Crown
This document provides guidance to support operation of the Cancer Drugs Fund in 2012-13. It replaces previous guidance for operation of the Cancer Drugs Fund in 2011/12. The Cancer Drugs Fund applies in England only.

Vitamin D testing – articles of interest : The Lancet



Vitamin D testing (see sidebar)

Vitamin D testing – Authors' reply : The Lancet



Vitamin D testing – Authors' reply : The Lancet


Linked Articles
Correspondence Vitamin D testing more information:
Correspondence Vitamin D testing more information
Correspondence Vitamin D testing more information
Correspondence Vitamin D testing more information

Patient empowerment—who empowers whom? : The Lancet



Patient empowerment—who empowers whom? : The Lancet


"What is patient empowerment? Over 250 participants discussed this question at the first European Conference on Patient Empowerment, recently held in Copenhagen, Denmark, by the European Network on Patient Empowerment (ENOPE 2012). The conference was convened under the auspices of the Danish Presidency of the European Union (EU), and organised by the WHO Regional Office for Europe, Denmark's Ministry of Health, the Danish Committee for Health Education, the Caerum Foundation of Switzerland, and the English Expert Patient's group......

Cochrane: YourHealthNet - navigating effective treatments with systematic reviews



YourHealthNet - navigating effective treatments with systematic reviews


The parts of a Cochrane systematic review and the information they contain - learning to navigate a review

Cochrane systematic reviews

Cochrane systematic reviews are the major output of the international organisation The Cochrane Collaboration, and over 4,000 Cochrane reviews are available online on The Cochrane Library. Because Cochrane review authors carry out their research with scientific rigour and follow detailed guidelines Cochrane reviews are considered a high quality source of research evidence.


David Tovey from The Cochrane Collaboration talks about systematic reviews.  


Explore the parts of a Cochrane systematic review

Systematic reviews are a complex mix of process and product - they report on the process review authors undertook, and the conclusions authors came to about what they found. All Cochrane systematic reviews follow the same format and methods; they have the same content in the same sections. This ensures their transparency and rigour.....

Healthnewsreview: The limitations of – and explosion in the number of – observational studies



The limitations of – and explosion in the number of – observational studies:

In the Wall Street Journal, Gautam Naik has a thoughtful piece, “Analytical Trend Troubles Scientists,” hitting on the limitations of – and the explosion in the number of – observational studies.  Excerpts:
“While the gold standard of medical research is the randomly controlled experimental study, scientists have recently rushed to pursue observational studies, which are much easier, cheaper and quicker to do. Costs for a typical controlled trial can stretch high into the millions; observational studies can be performed for tens of thousands of dollars.
In an observational study there is no human intervention. Researchers simply observe what is happening during the course of events, or they analyze previously gathered data and draw conclusions. In an experimental study, such as a drug trial, investigators prompt some sort of change—by giving a drug to half the participants, say—and then make inferences.
But observational studies, researchers say, are especially prone to methodological and statistical biases that can render the results unreliable. Their findings are much less replicable than those drawn from controlled research. Worse, few of the flawed findings are spotted—or corrected—in the published literature.
“You can troll the data, slicing and dicing it any way you want,” says S. Stanley Young of the U.S. National Institute of Statistical Sciences. Consequently, “a great deal of irresponsible reporting of results is going on.”
Despite such concerns among researchers, observational studies have never been more popular.
Nearly 80,000 observational studies were published in the period 1990-2000 across all scientific fields, according to an analysis performed for The Wall Street Journal by Thomson Reuters. In the following period, 2001-2011, the number of studies more than tripled to 263,557, based on a search of Thomson Reuters Web of Science, an index of 11,600 peer-reviewed journals world-wide. The analysis likely doesn’t capture every observational study in the literature, but it does indicate a pattern of growth over time.
A vast array of claims made in medicine, public health and nutrition are based on observational studies, as are those about the environment, climate change and psychology.”
The article addresses the “hot area of medical research” – the search for biomarkers.
“The presence or absence of the biomarkers in a patient’s blood, some theorized, could indicate a higher or lower risk for heart disease—the biggest killer in the Western world.
Yet these biomarkers “are either completely worthless or there are only very small effects” in predicting heart disease, says John Ioannidis of Stanford University, who extensively analyzed two decades’ worth of biomarker research and published his findings in Circulation Research journal in March. Many of the studies, he found, were undermined by statistical biases, and many of the biomarkers showed very little predictive ability of heart disease.
His conclusion is widely upheld by other scientists: Just because two events are statistically associated in a study, it doesn’t mean that one necessarily sets off the other. What is merely suggestive can be mistaken as causal.
That partly explains why observational studies in general can be replicated only 20% of the time, versus 80% for large, well-designed randomly controlled trials, says Dr. Ioannidis. Dr. Young, meanwhile, pegs the replication rate for observational data at an even lower 5% to 10%.
Whatever the figure, it suggests that a lot more of these studies are getting published. Those papers can often trigger pointless follow-on research and affect real-world practices.”
But the story also appropriately points out the contribution obervational studies have made:
“Observational studies do have many valuable uses. They can offer early clues about what might be triggering a disease or health outcome. For example, it was data from observational trials that flagged the increased risk of heart attacks posed by the arthritis drug Vioxx. And it was observational data that helped researchers establish the link between smoking and lung cancer.”
I have written many times about the weakness of news stories that fail to point out the limitations of observational studies and – more specifically – stories that use causal language to describe the findings from observational studies that can “only” point to statistical associations.
News consumers and health care consumers need to better understand the limitations of all studies – including randomized clinical trials.

paywalled: Risk of Colonic Neoplasia After Proctectomy for Rectal Cancer in Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome)



abstract

Abstract

Objective: To define the neoplastic risk in the remaining colon after proctectomy for rectal cancer in patients with hereditary nonpolyposis colorectal cancer (HNPCC). (Lynch Syndrome)

Conclusions: Surgeons and patients need to be aware of substantial risk for metachronous neoplasia after proctectomy. Selection of operation should be individualized, but total proctocolectomy and ileoanal pouch should be strongly considered. If patients undergo proctectomy alone, close surveillance is mandatory.

Explaining High Health Care Spending in the United States: An International Comparison of Supply, Utilization, Prices, and Quality - The Commonwealth Fund



Blogger's Note: some interesting comparisons on a variety of comparables including in-hospital 30 day mortality rates, breast/cervical/colorectal cancer survival rates, diagnostic imaging; comparisons of countries:


Explaining High Health Care Spending in the United States: An International Comparison of Supply, Utilization, Prices, and Quality - The Commonwealth Fund

Overview

This analysis uses data from the Organization for Economic Cooperation and Development and other sources to compare health care spending, supply, utilization, prices, and quality in 13 industrialized countries: Australia, Canada, Denmark, France, Germany, Japan, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States......

paywalled: Evaluation of Society of Gynecologic Oncologists (SGO) Ovarian Cancer Quality Surgical Measures



Evaluation of Society of Gynecologic Oncologists (SGO) Ovarian Cancer Quality Surgical Measures: Publication year: 2012

Source: Gynecologic Oncology



Objectives
The Society of Gynecologic Oncologists has developed two measures to assess & improve the surgical care of patients with ovarian cancer (1) description of residual disease following cytoreduction and (2) adequacy of surgical staging. Our aim was to establish baseline surgeon compliance with these two measures.

Methods
A retrospective review of patients with ovarian, fallopian tube or peritoneal cancer undergoing surgery between 7/1/2006 and 7/1/2011 for the purposes of staging and/or cytoreduction was performed at the University of Washington and Geisinger Medical Center. Operative and pathology reports were reviewed to obtain information pertaining to stage, histology, residual disease after surgery and the extent of surgical staging.

Results 
537 cases were identified; 91% with ovarian cancer. 61% of patients had at least stage IIIC disease; 15% had recurrent disease and 16% had neoadjuvant therapy. For patients with stage I-IIIB disease, 74% had full surgical staging, 10% did not have full surgical staging but documented the reason for this in the operative report; 15% did not have full surgical staging, no reason was noted. 25% of all operative reports lacked documentation of residual disease with 40% documenting no gross residual disease, 18% with residual disease<1cm and 18% had suboptimal debulking with>1cm disease remaining. There was a statistically significant increase in appropriate documentation of amount of residual disease over time (p<0.001).

Conclusions
 Our study sets benchmarks for evaluation of documentation in gynecologic oncology centers. Improved documentation and staging will allow for equivalent standards of care across institutions.

Wednesday, May 02, 2012

paywalled Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland



Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland: Publication year: 2012

Source:Gynecologic Oncology

Objective Primary fallopian tube carcinoma (PFTC) is a rare malignancy and only sparse data exist on its possible association with postmenopausal hormone therapy (HT). We therefore studied this association in a nationwide cohort of Finnish HT users.

Conclusions The long-term, sequential use of EPT associates with an increased risk for PFTC. In absolute terms, 4 additional cases of PFTC would be detected in 10-year follow-up of 10,000 women who have used EPT for at least 5 years

Debate Over Who Should Be Allowed to Administer Anesthesia Moves to Courts - NYTimes.com



Debate Over Who Should Be Allowed to Administer Anesthesia Moves to Courts - NYTimes.com

Family history: Still relevant in the genomics era - Cleveland Clinic



Family history: Still relevant in the genomics era

 Key points

  • The family history is an underused tool for predicting the risk of disease and for personalizing preventive care.
  • Barriers to the appropriate collection and use of the family history include concerns over the reliability of patient reporting, a lack of time and reimbursement, and provider knowledge gaps.
  • Use of family history to inform genetic testing for hereditary cancer syndromes has been shown to improve outcomes and may reduce overall health care costs.
  • Future solutions need to focus on creating time-effective ways to collect and analyze the family history, and on developing innovative methods of educating medical providers at all levels of training as to how to apply the family history in clinical practice. 

Study Downplays Risk of CT Scans - MedicineNet



Blogger's Note: cancer patients know this; the concern is 'excess' or unnecessary scans (as indicated in the article)

Study Downplays Risk of CT Scans - MedicineNet

"More often than not, patients should be getting that CT scan because the risk of the underlying cause is higher than from radiation."

"...The findings were similar -- with deaths ranging from 2 percent to 33 percent -- in the more than 15,000 who got abdominal CTs. The researchers think 23 people in the entire group would have gotten cancer due to radiation exposure."

""In the patients getting 15 or more scans, all of them had pretty significant disease, where their expected mortality was likely to occur much sooner than the chances of the radiation-induced cancer taking effect," Zondervan said. In other words: Those who were the sickest, requiring the most CT scans, would probably die before any cancer caused by the CT radiation could start hurting them."

Tuesday, May 01, 2012

Medscape Oncologist Compensation Report: 2012 Results - U.S.



 Blogger's Note: not broken down specifically to the sub-specializtion of gyn/oncology, patients/public perceptions of physician's compensation/expenses, income demographics, time spent with patients, physician hours of work, satisfaction with profession.....

Medscape Oncologist Compensation Report: 2012 Results